3613 Stock Overview
Engages in the manufacture, retail, and wholesale of healthcare products and Chinese medicine to wholesalers and individuals.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Beijing Tong Ren Tang Chinese Medicine Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$8.60 |
| 52 Week High | HK$14.98 |
| 52 Week Low | HK$8.25 |
| Beta | 0.40 |
| 11 Month Change | -4.55% |
| 3 Month Change | -8.41% |
| 1 Year Change | -36.67% |
| 33 Year Change | -21.10% |
| 5 Year Change | -29.62% |
| Change since IPO | 31.70% |
Recent News & Updates
Recent updates
Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk
Feb 05
Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Jan 03A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Sep 28Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today
Jul 12Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?
Mar 29Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28
Apr 28Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28
Mar 25Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?
Oct 27Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 28Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Mar 11What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Feb 04Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?
Jan 18
Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?
Dec 29Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Dec 11Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Nov 23Shareholder Returns
| 3613 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 0.1% | -4.0% | -2.7% |
| 1Y | -36.7% | -10.8% | -7.5% |
Return vs Industry: 3613 underperformed the Hong Kong Pharmaceuticals industry which returned -10.8% over the past year.
Return vs Market: 3613 underperformed the Hong Kong Market which returned -7.5% over the past year.
Price Volatility
| 3613 volatility | |
|---|---|
| 3613 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.1% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 3613 has not had significant price volatility in the past 3 months.
Volatility Over Time: 3613's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1669 | 798 | Wang Chi | www.tongrentangcm.com |
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of healthcare products and Chinese medicine to wholesalers and individuals. The company operates through three segments: Hong Kong, Mainland China, and Overseas. It also offers Chinese medical consultation and treatment services.
Beijing Tong Ren Tang Chinese Medicine Company Limited Fundamentals Summary
| 3613 fundamental statistics | |
|---|---|
| Market cap | HK$6.97b |
| Earnings (TTM) | HK$540.39m |
| Revenue (TTM) | HK$1.52b |
13.3x
P/E Ratio4.7x
P/S RatioIs 3613 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3613 income statement (TTM) | |
|---|---|
| Revenue | HK$1.52b |
| Cost of Revenue | HK$477.70m |
| Gross Profit | HK$1.05b |
| Other Expenses | HK$506.85m |
| Earnings | HK$540.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.65 |
| Gross Margin | 68.67% |
| Net Profit Margin | 35.44% |
| Debt/Equity Ratio | 0.008% |
How did 3613 perform over the long term?
See historical performance and comparison